Marché européen des médicaments contre la dyspepsie, par type (dyspepsie organique, dyspepsie non ulcéreuse, dyspepsie induite par les médicaments et autres), type de traitement (médicaments et chirurgie), type de médicament (de marque et générique), ordonnance (médicaments sans ordonnance et médicaments sur ordonnance), voie d'administration (orale et injectable), sexe (homme et femme), utilisateur final (hôpitaux, cliniques, établissements de soins à domicile, cliniques spécialisées, centres de chirurgie ambulatoire , instituts de recherche universitaires et gouvernementaux et autres), canal de distribution (appels d'offres directs et ventes au détail) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché européen des médicaments contre la dyspepsie
Le marché européen des médicaments contre la dyspepsie devrait croître au cours de la période de prévision en raison de la prévalence croissante de la dyspepsie et de l'adoption croissante de modes de vie malsains. Le marché est également influencé par l'augmentation de la prévalence des troubles métaboliques. Cependant, le marché européen des médicaments contre la dyspepsie devrait être entravé par les effets secondaires possibles des médicaments utilisés pour la dyspepsie et la préférence croissante pour les remèdes naturels et à base de plantes. Le vieillissement croissant de la population et l'augmentation du nombre d'approbations de médicaments devraient constituer des opportunités de croissance du marché. Cependant, des réglementations strictes et un manque de sensibilisation à la dyspepsie au sein de la population devraient remettre en cause la croissance du marché.
Data Bridge Market Research analyse que le marché européen des médicaments contre la dyspepsie devrait croître à un TCAC de 4,7 % au cours de la période de prévision de 2023 à 2030.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en milliers, volumes en unités et prix en USD |
|
Segments couverts |
Type (dyspepsie organique, dyspepsie non ulcéreuse, dyspepsie induite par des médicaments et autres), type de traitement (médicaments et chirurgie), type de médicament (de marque et générique), ordonnance (médicaments sans ordonnance et médicaments sur ordonnance), voie d'administration (orale et injectable), sexe (homme et femme), utilisateur final (hôpitaux, cliniques, établissements de soins à domicile, cliniques spécialisées, centres de chirurgie ambulatoire, instituts de recherche universitaires et gouvernementaux et autres), canal de distribution (ventes directes et au détail) |
|
Pays couverts |
Allemagne, Royaume-Uni, France, Italie, Espagne, Pays-Bas, Russie, Suisse, Turquie, Belgique, Danemark, Suède, Pologne, Norvège, Finlande et reste de l'Europe |
|
Acteurs du marché couverts |
Bayer AG, Cadila Pharmaceuticals, Sanofi, Lupin, Abbott, Perrigo Company plc, AstraZeneca, Procter & Gamble et Reckitt Benckiser, entre autres |
Définition du marché
La dyspepsie, communément appelée indigestion, est une douleur et un inconfort ressentis dans l'abdomen après avoir mangé. C'est généralement le signe d'une maladie sous-jacente comme le RGO (reflux gastro-œsophagien), la vésicule biliaire et un ulcère. Le traitement de la dyspepsie dépend de la cause et de la gravité. Traiter une maladie sous-jacente ou changer le traitement d'une personne réduira la dyspepsie. La dyspepsie est divisée en deux catégories principales : la dyspepsie « organique » et la « dyspepsie fonctionnelle » (DF). Les causes organiques de la dyspepsie sont l'ulcère gastroduodénal, le reflux gastro-œsophagien, le cancer gastrique ou œsophagien, les troubles pancréatiques ou biliaires, l'intolérance aux aliments ou aux médicaments et d'autres maladies infectieuses ou systémiques. La dyspepsie fonctionnelle est un terme désignant les symptômes récurrents d'un mal d'estomac qui n'ont pas de cause évidente. La dyspepsie fonctionnelle est également appelée dyspepsie non ulcéreuse.
Dynamique du marché européen des médicaments contre la dyspepsie
Cette section traite de la compréhension des moteurs, des avantages, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :
CONDUCTEURS
- Prévalence croissante de la dyspepsie
La dyspepsie, communément appelée indigestion, est un trouble gastro-intestinal qui touche des millions de personnes en Europe. Il s'agit d'une affection qui provoque une gêne, des douleurs et une sensation de plénitude ou de ballonnement dans la partie supérieure de l'abdomen. La dyspepsie peut être causée par divers facteurs tels que le fait de manger trop vite, de consommer des aliments épicés ou gras, ou comme effet secondaire d'un médicament.
La prévalence croissante de la dyspepsie est l'un des principaux facteurs de croissance du marché des médicaments contre la dyspepsie. L'incidence croissante de la dyspepsie peut être attribuée à plusieurs facteurs tels que les changements de mode de vie, les habitudes alimentaires et le vieillissement de la population. À mesure que les gens vieillissent, ils sont plus sensibles aux problèmes digestifs, notamment à la dyspepsie. Avec le nombre croissant de personnes âgées, la demande de médicaments contre la dyspepsie augmente.
En outre, différentes maladies digestives telles que le syndrome du côlon irritable, la gastroparésie, la gastrite et l'ulcère gastroduodénal provoquent également une dyspepsie, en raison de la prévalence croissante de la maladie mentionnée. Ainsi, la prévalence croissante de la dyspepsie et d'autres troubles digestifs provoquant une dyspepsie devrait agir comme moteur de la croissance du marché. L'utilisation de médicaments contre la dyspepsie pour soulager les symptômes de la dyspepsie et traiter la dyspepsie a le potentiel d'améliorer les résultats des patients et de réduire le fardeau de la dyspepsie. Ainsi, la prévalence croissante de la dyspepsie stimule la demande de médicaments contre la dyspepsie dans le monde entier pour augmenter l'incidence et la prévalence de la dyspepsie au sein de la population.
- Augmentation de l'adoption de modes de vie malsains
Ces dernières années, on a observé une augmentation du nombre de modes de vie malsains, ce qui a contribué à une augmentation de la prévalence de la dyspepsie. Des choix de vie malsains tels qu’une alimentation riche en aliments transformés, le manque d’exercice et la consommation excessive d’alcool peuvent tous contribuer à la dyspepsie.
En conséquence, la demande de médicaments contre la dyspepsie a augmenté, car les personnes cherchent à soulager leurs symptômes. Le marché des médicaments contre la dyspepsie a répondu à cette demande avec une variété de médicaments, notamment des inhibiteurs de la pompe à protons, des antagonistes des récepteurs H2 et des antiacides.
L’adoption croissante de modes de vie malsains peut être attribuée à plusieurs facteurs, notamment les changements dans les habitudes alimentaires, l’augmentation du niveau de stress et la sédentarité. La vie moderne est souvent caractérisée par de longues heures de travail, des niveaux de stress élevés et un accès facile à la restauration rapide et à d’autres options malsaines. Ces facteurs peuvent contribuer à la dyspepsie et à d’autres affections connexes telles que le reflux gastro-œsophagien (RGO).
En conclusion, la dyspepsie est une affection courante qui peut être causée par divers facteurs, notamment des choix de vie malsains. L’adoption croissante de modes de vie malsains a contribué à une augmentation de la prévalence de la dyspepsie, et la demande de médicaments efficaces contre la dyspepsie a augmenté en conséquence, ce qui devrait servir de moteur à la croissance du marché.
OPPORTUNITÉ
- Vieillissement de la population
Selon les estimations, le nombre de personnes âgées de 65 ans et plus devrait atteindre 1,5 milliard d'ici 2050, ce qui montre que la population mondiale vieillit rapidement. Les personnes âgées courent un risque plus élevé de développer des problèmes de santé chroniques. Cela comprend les troubles digestifs tels que la dyspepsie, qui peuvent survenir en raison du vieillissement.
Le vieillissement de la population et la croissance de la population représentent une opportunité considérable pour l'expansion du marché des médicaments contre la dyspepsie. De plus en plus de personnes souffrent de problèmes digestifs, ce qui accroît le besoin de traitements efficaces capables de réduire la gravité de leurs symptômes et d'améliorer leur qualité de vie globale.
De plus, le traitement de la dyspepsie doit être adapté spécifiquement aux besoins d’une population vieillissante. Les personnes âgées peuvent souffrir de plusieurs maladies chroniques et prendre plusieurs médicaments en même temps, ce qui peut augmenter le risque d’interactions médicamenteuses négatives et d’effets secondaires. Par conséquent, il existe une demande pour des médicaments contre la dyspepsie qui sont à la fois sans risque et efficaces lorsqu’ils sont administrés aux personnes âgées. En outre, avec l’âge, les personnes perdent également leur force physique et leur immunité, ce qui entraîne une prévalence croissante de plusieurs maladies gastro-intestinales, dont la dyspepsie.
Par conséquent, l'augmentation du vieillissement de la population provoquant la dyspepsie et ses symptômes et la préférence de la population pour les soins de santé préventifs devraient constituer une opportunité pour la croissance du marché des médicaments contre la dyspepsie.
RETENUE/DÉFI
- Manque de sensibilisation de la population à la dyspepsie
La pénurie de compétences a déjà des répercussions sur le pays, avec un nombre croissant de personnes obligées d'attendre plus de six mois pour leurs traitements dentaires. Il existe une pénurie de professionnels qualifiés dans le domaine des médicaments contre la dyspepsie dans les pays émergents ou en développement en raison des progrès techniques, des infrastructures de base et de plusieurs autres facteurs.
Le manque de professionnels qualifiés est en partie dû à la formation rigoureuse requise pour devenir un professionnel dentaire ainsi qu'à la concurrence sur le marché du travail. De plus, les dentistes qualifiés ont besoin de davantage d'assistants dentaires officiellement formés et agréés pour aider à maintenir et à accroître l'accès aux soins bucco-dentaires afin d'exploiter et d'exécuter des systèmes technologiques avancés tels que les systèmes de médicaments contre la dyspepsie.
Les pays émergents manquent de professionnels qualifiés qui ne peuvent pas utiliser efficacement les nouvelles technologies. Cela pourrait créer un défi pour l'émergence de nouvelles technologies sur le marché, car ces pays retardent l'apparition des avancées technologiques sur le marché.
Développements récents
- En avril 2023, Sanofi a annoncé avoir finalisé l'acquisition de Provention Bio, Inc. Cette acquisition a aidé l'entreprise à développer ses activités en médecine générale.
- En juillet 2022, ANI Pharmaceuticals, Inc. a annoncé l'achat de quatre demandes abrégées de nouveaux médicaments (ANDA) auprès d'Oakrum Pharma, LLC, une société biopharmaceutique privée.
Segmentation du marché européen des médicaments contre la dyspepsie
Le marché européen des médicaments contre la dyspepsie est segmenté en type, type de traitement, type de médicament, prescription, voie d'administration, sexe, utilisateur final et canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
Taper
- Dyspepsie non ulcéreuse
- Dyspepsie organique
- Dyspepsie induite par les médicaments
- Autres
En fonction du type, le marché européen des médicaments contre la dyspepsie est segmenté en dyspepsie organique, dyspepsie non ulcéreuse, dyspepsie induite par les médicaments et autres.
Type de traitement
- Médicament
- Chirurgie
En fonction du type de traitement, le marché européen des médicaments contre la dyspepsie est segmenté en médicaments et en chirurgie.
Type de médicament
- De marque
- Générique
En fonction du type de médicament, le marché européen des médicaments contre la dyspepsie est segmenté en médicaments génériques et de marque.
Ordonnance
- Sans médicaments sur ordonnance
- Médicaments sur ordonnance
Sur la base de la prescription, le marché européen des médicaments contre la dyspepsie est segmenté en médicaments sans ordonnance et médicaments sur ordonnance.
Voie d'administration
- Oral
- Injectable
En fonction de la voie d’administration, le marché européen des médicaments contre la dyspepsie est segmenté en médicaments oraux et injectables.
Genre
- Mâle
- Femelle
En fonction du sexe, le marché européen des médicaments contre la dyspepsie est segmenté en hommes et en femmes.
Utilisateur final
- Hôpitaux
- Cliniques
- Cadres de soins à domicile
- Cliniques spécialisées
- Centres ambulatoires
- Instituts de recherche universitaires et gouvernementaux
- Autres
En fonction de l’utilisateur final, le marché européen des médicaments contre la dyspepsie est segmenté en hôpitaux, cliniques, établissements de soins à domicile, cliniques spécialisées, centres de chirurgie ambulatoire, instituts de recherche universitaires et gouvernementaux, et autres.
Canal de distribution
- Appel d'offres direct
- Ventes au détail
En fonction du canal de distribution, le marché européen des médicaments contre la dyspepsie est segmenté en appels d’offres directs et ventes au détail.
Analyse/perspectives régionales du marché européen des médicaments contre la dyspepsie
Le marché européen des médicaments contre la dyspepsie est analysé et des informations et tendances sur la taille du marché sont fournies en fonction du type, du type de traitement, du type de médicament, de la prescription, de la voie d'administration, du sexe, de l'utilisateur final et du canal de distribution.
Les pays couverts dans ce rapport de marché sont l'Allemagne, le Royaume-Uni, la France, l'Italie, l'Espagne, les Pays-Bas, la Russie, la Suisse, la Turquie, la Belgique, le Danemark, la Suède, la Pologne, la Norvège, la Finlande et le reste de l'Europe.
L'Allemagne devrait dominer le marché européen des médicaments contre la dyspepsie en raison de l'amélioration de la technologie et de la fiabilité des services de santé. La demande dans cette région devrait être stimulée par l'augmentation de la dyspepsie liée au vieillissement de la population.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour chaque pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales et l'impact des tarifs nationaux et des routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des médicaments contre la dyspepsie en Europe
Le paysage concurrentiel du marché européen des médicaments contre la dyspepsie fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, la présence en Europe, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché.
Certains des principaux acteurs du marché opérant sur le marché sont Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble et Reckitt Benckiser, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE DYSPEPSIA DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END-USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA
7 INDUSTRY INSIGHTS:
8 EUROPE DYSPEPSIA DRUG MARKET, REGULATION
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING PREVALENCE OF DYSPEPSIA
9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE
9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS
9.2 RESTRAINTS
9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA
9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES
9.3 OPPORTUNITIES
9.3.1 GROWING AGING POPULATION
9.3.2 RISE IN THE DRUG APPROVAL
9.4 CHALLENGES
9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION
9.4.2 STRINGENT REGULATIONS
10 EUROPE DYSPEPSIA DRUG MARKET, BY TYPE
10.1 OVERVIEW
10.2 NON-ULCER DYSPEPSIA
10.3 ORGANIC DYSPEPSIA
10.4 DRUG INDUCED DYSPEPSIA
10.5 OTHERS
11 EUROPE DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 DRUGS
11.2.1.1 ANTACIDS
11.2.1.1.1 PROTON PUMP INHIBITORS (PPI’S)
11.2.1.1.1.1 OMEPRAZOLE
11.2.1.1.1.2 LANSOPRAZOLE
11.2.1.1.1.3 ESOMEPRAZOLE
11.2.1.1.1.4 OTHERS
11.2.1.1.2 H2 BLOCKERS
11.2.1.1.2.1 CIMETIDINE
11.2.1.1.2.2 FAMOTIDINE
11.2.1.1.2.3 NIZATIDINE
11.2.1.1.2.4 RANITIDINE
11.2.1.1.2.5 OTHERS
11.2.1.2 GASTRIC PROKINETIC GENDERNTS
11.2.1.2.1 MOSAPRIDE CITRATE
11.2.1.2.2 METOCLOPRAMIDE
11.2.1.2.3 CISAPRIDE
11.2.1.2.4 ITOPRIDE HYDROCHLORIDE
11.2.1.2.5 DOMPERIDONE
11.2.1.2.6 OTHERS
11.2.1.3 ANTIBIOTICS
11.2.1.3.1 REFAXIMIN
11.2.1.3.2 AMOXICILLIN
11.2.1.3.3 CLARITHROMYCIN
11.2.1.3.4 METRONIDAZOLE
11.2.1.3.5 LEVOFLOXACIN
11.2.1.3.6 TETRACYCLINE
11.2.1.3.7 OTHERS
11.2.1.4 OTHERS
11.2.2 NON- DRUGS
11.2.2.1 PROBIOTICS
11.2.2.1.1 LACTOBACILLUS
11.2.2.1.2 BIFIDOBACTERIUM
11.2.2.1.3 BACILLUS
11.2.2.1.4 STREPTOCOCCUS
11.2.2.1.5 OTHERS
11.2.2.2 PREBIOTICS
11.3 SURGERY
12 EUROPE DYSPEPSIA DRUG MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERIC
12.3 BRANDED
13 EUROPE DYSPEPSIA DRUG MARKET, BY PRESCRIPTION
13.1 OVERVIEW
13.2 WITHOUT PRESCRIPTION DRUGS
13.3 PRESCRIPTION DRUGS
14 EUROPE DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 TABLETS
14.2.2 CAPSULES
14.3 INJECTABLE
15 EUROPE DYSPEPSIA DRUG MARKET, BY GENDER
15.1 OVERVIEW
15.2 FEMALE
15.2.1 30-50 YEARS
15.2.2 MORE THAN 50 YEARS
15.2.3 AGE LESS THAN 30
15.3 MALE
15.3.1 30-50 YEARS
15.3.2 MORE THAN 50 YEARS
15.3.3 AGE LESS THAN 30
16 EUROPE DYSPEPSIA DRUG MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.2.1 TYPE
16.2.1.1 PUBLIC
16.2.1.2 PRIVATE
16.2.2 TIER
16.2.2.1 TIER 3
16.2.2.2 TIER 2
16.2.2.3 TEIR 1
16.3 CLINICS
16.4 HOMECARE SETTINGS
16.5 SPECIALTY CLINICS
16.6 AMBULATORY CENTERS
16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
16.8 OTHERS
17 EUROPE DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 RETAIL SALES
17.2.1 REATIL PHARMACY
17.2.2 HOSPITAL PHARMACY
17.2.3 ONLINE PHARMACY
17.3 DIRECT TENDER
18 EUROPE DYSPEPSIA DRUG MARKET, BY REGION
18.1 EUROPE
18.1.1 GERMANY
18.1.2 U.K.
18.1.3 ITALY
18.1.4 FRANCE
18.1.5 SPAIN
18.1.6 RUSSIA
18.1.7 SWITZERLAND
18.1.8 TURKEY
18.1.9 BELGIUM
18.1.10 NETHERLANDS
18.1.11 DENMARK
18.1.12 SWEDEN
18.1.13 POLAND
18.1.14 NORWAY
18.1.15 FINLAND
18.1.16 REST OF EUROPE
19 EUROPE DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: EUROPE
20 SWOT ANALYSIS
21 EUROPE DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS
21.1 SANOFI
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENT
21.2 LUPIN
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 MANKIND PHARMA
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENT
21.4 ASTRAZENECA
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENT
21.5 BAYER AG
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENT
21.6 ABBOTT
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ANI PHARMACEUTICALS, INC.
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 AOSAIKANG PHARMACEUTICAL CO., LTD.
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 ASTERISK LABORATORIES (I) PVT. LTD
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENT
21.1 CADILA PHARMACEUTICALS
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 COMPANY SHARE ANALYSIS
21.10.4 PRODUCT PORTFOLIO
21.10.5 RECENT DEVELOPMENT
21.11 HANMI PHARM. CO., LTD.
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE ANALYSIS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENT
21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 OTSUKA PHARMACEUTICAL CO., LTD.
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 PERRIGO COMPANY PLC
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 PRESTIGE CONSUMER HEALTHCARE, INC.
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENT
21.16 PROCTER & GAMBLE
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENT
21.17 RECKITT BENCKISER.
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENT
21.18 REDHILL BIOPHARMA LTD
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENT
21.19 SALIX PHARMACEUTICALS OR ITS AFFILIATES (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENT
21.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 WOODWARD PHARMA
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENT
21.22 ZERIA PHARMACEUTICAL CO., LTD.
21.22.1 COMPANY SNAPSHOT
21.22.2 REVENUE ANALYSIS
21.22.3 PRODUCT PORTFOLIO
21.22.4 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 EUROPE NON-ULCER DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 3 EUROPE ORGANIC DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 4 EUROPE DRUG INDUCED DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 5 EUROPE OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 6 EUROPE DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 EUROPE MEDICATION IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 8 EUROPE MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 EUROPE DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 EUROPE ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 EUROPE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 EUROPE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 EUROPE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 14 EUROPE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 15 EUROPE NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 EUROPE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 EUROPE SURGERY IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 18 EUROPE DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 19 EUROPE GENERIC IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 20 EUROPE BRANDED IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 21 EUROPE DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 22 EUROPE WITHOUT PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 23 EUROPE PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 24 EUROPE DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 25 EUROPE ORAL IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 26 EUROPE ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 27 EUROPE INJECTABLE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 28 EUROPE DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 29 EUROPE FEMALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 30 EUROPE FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 31 EUROPE MALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 32 EUROPE MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 33 EUROPE DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 34 EUROPE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 35 EUROPE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 EUROPE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 37 EUROPE CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 38 EUROPE HOMECARE SETTINGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 39 EUROPE SPECIALTY CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 40 EUROPE AMBULATORY CENTERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 41 EUROPE ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 42 EUROPE OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 43 EUROPE DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 44 EUROPE RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 45 EUROPE RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 46 EUROPE DIRECT TENDER IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 47 EUROPE DYSPEPSIA DRUG MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 48 EUROPE DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 EUROPE DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 EUROPE MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 51 EUROPE DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 EUROPE ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 53 EUROPE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 EUROPE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 55 EUROPE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 EUROPE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 57 EUROPE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 58 EUROPE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 59 EUROPE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 EUROPE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 61 EUROPE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 62 EUROPE NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 EUROPE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 64 EUROPE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 65 EUROPE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 66 EUROPE DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 67 EUROPE DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 68 EUROPE DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 69 EUROPE ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 70 EUROPE DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 71 EUROPE FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 72 EUROPE MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 73 EUROPE DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 74 EUROPE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 75 EUROPE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 76 EUROPE DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 77 EUROPE RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 78 GERMANY DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 79 GERMANY DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 GERMANY MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 GERMANY DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 GERMANY ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 83 GERMANY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 84 GERMANY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 85 GERMANY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 86 GERMANY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 87 GERMANY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 88 GERMANY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 89 GERMANY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 90 GERMANY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 91 GERMANY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 92 GERMANY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 93 GERMANY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 94 GERMANY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 95 GERMANY NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 96 GERMANY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 97 GERMANY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 98 GERMANY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 99 GERMANY DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 100 GERMANY DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 101 GERMANY DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 102 GERMANY ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 103 GERMANY DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 104 GERMANY FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 105 GERMANY MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 106 GERMANY DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 107 GERMANY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 108 GERMANY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 109 GERMANY DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 110 GERMANY RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 111 U.K. DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 U.K. DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 U.K. MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 U.K. DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 U.K. ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 116 U.K. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 117 U.K. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 118 U.K. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 119 U.K. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 120 U.K. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 121 U.K. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 122 U.K. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 123 U.K. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 124 U.K. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 125 U.K. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 126 U.K. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 127 U.K. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 128 U.K. NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 129 U.K. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 130 U.K. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 131 U.K. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 132 U.K. DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 133 U.K. BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 134 U.K. DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 135 U.K. DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 136 U.K. ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 137 U.K. DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 138 U.K. FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 139 U.K. MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 140 U.K. DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 141 U.K. HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 142 U.K. HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 143 U.K. DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 144 U.K. RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 145 ITALY DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 146 ITALY DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 147 ITALY MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 148 ITALY DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 149 ITALY ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 150 ITALY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 151 ITALY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 152 ITALY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 153 ITALY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 154 ITALY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 155 ITALY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 156 ITALY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 ITALY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 158 ITALY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 159 ITALY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 160 ITALY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 161 ITALY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 162 ITALY NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 163 ITALY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 164 ITALY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 165 ITALY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 166 ITALY DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 167 ITALY DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 168 ITALY DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 169 ITALY ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 170 ITALY DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 171 ITALY FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 172 ITALY MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 173 ITALY DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 174 ITALY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 175 ITALY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 176 ITALY DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 177 ITALY RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 178 FRANCE DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 179 FRANCE DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 180 FRANCE MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 181 FRANCE DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 182 FRANCE ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 183 FRANCE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 184 FRANCE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 185 FRANCE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 186 FRANCE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 187 FRANCE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 188 FRANCE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 189 FRANCE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 FRANCE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 191 FRANCE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 192 FRANCE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 FRANCE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 194 FRANCE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 195 FRANCE NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 196 FRANCE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 197 FRANCE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 198 FRANCE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 199 FRANCE DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 200 FRANCE DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 201 FRANCE DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 202 FRANCE ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 203 FRANCE DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 204 FRANCE FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 205 FRANCE MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 206 FRANCE DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 207 FRANCE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 208 FRANCE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 209 FRANCE DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 210 FRANCE RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 211 SPAIN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 212 SPAIN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 213 SPAIN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 SPAIN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 215 SPAIN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 216 SPAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 217 SPAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 218 SPAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 219 SPAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 SPAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 221 SPAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 222 SPAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 223 SPAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 224 SPAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 225 SPAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 226 SPAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 227 SPAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 228 SPAIN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 229 SPAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 230 SPAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 231 SPAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 232 SPAIN BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 233 SPAIN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 234 SPAIN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 235 SPAIN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 236 SPAIN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 237 SPAIN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 238 SPAIN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 239 SPAIN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 240 SPAIN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 241 SPAIN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 242 SPAIN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 243 SPAIN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 244 RUSSIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 RUSSIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 RUSSIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 247 RUSSIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 248 RUSSIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 249 RUSSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 250 RUSSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 251 RUSSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 252 RUSSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 253 RUSSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 254 RUSSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 255 RUSSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 256 RUSSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 257 RUSSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 258 RUSSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 259 RUSSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 260 RUSSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 261 RUSSIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 262 RUSSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 263 RUSSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 264 RUSSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 265 RUSSIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 266 RUSSIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 267 RUSSIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 268 RUSSIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 269 RUSSIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 270 RUSSIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 271 RUSSIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 272 RUSSIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 273 RUSSIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 274 RUSSIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 275 RUSSIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 276 RUSSIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 277 SWITZERLAND DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 278 SWITZERLAND DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 279 SWITZERLAND MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 280 SWITZERLAND DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 281 SWITZERLAND ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 282 SWITZERLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 283 SWITZERLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 284 SWITZERLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 285 SWITZERLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 286 SWITZERLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 287 SWITZERLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 288 SWITZERLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 289 SWITZERLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 290 SWITZERLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 291 SWITZERLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 292 SWITZERLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 293 SWITZERLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 294 SWITZERLAND NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 295 SWITZERLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 296 SWITZERLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 297 SWITZERLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 298 SWITZERLAND DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 299 SWITZERLAND DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 300 SWITZERLAND DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 301 SWITZERLAND ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 302 SWITZERLAND DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 303 SWITZERLAND FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 304 SWITZERLAND MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 305 SWITZERLAND DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 306 SWITZERLAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 307 SWITZERLAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 308 SWITZERLAND DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 309 SWITZERLAND RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 310 TURKEY DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 311 TURKEY DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 312 TURKEY MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 313 TURKEY DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 314 TURKEY ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 315 TURKEY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 316 TURKEY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 317 TURKEY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 318 TURKEY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 319 TURKEY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 320 TURKEY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 321 TURKEY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 322 TURKEY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 323 TURKEY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 324 TURKEY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 325 TURKEY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 326 TURKEY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 327 TURKEY NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 328 TURKEY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 329 TURKEY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 330 TURKEY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 331 TURKEY DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 332 TURKEY DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 333 TURKEY DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 334 TURKEY ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 335 TURKEY DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 336 TURKEY FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 337 TURKEY MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 338 TURKEY DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 339 TURKEY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 340 TURKEY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 341 TURKEY DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 342 TURKEY RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 343 BELGIUM DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 344 BELGIUM DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 345 BELGIUM MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 346 BELGIUM DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 347 BELGIUM ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 348 BELGIUM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 349 BELGIUM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 350 BELGIUM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 351 BELGIUM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 352 BELGIUM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 353 BELGIUM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 354 BELGIUM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 355 BELGIUM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 356 BELGIUM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 357 BELGIUM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 358 BELGIUM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 359 BELGIUM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 360 BELGIUM NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 361 BELGIUM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 362 BELGIUM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 363 BELGIUM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 364 BELGIUM DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 365 BELGIUM DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 366 BELGIUM DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 367 BELGIUM ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 368 BELGIUM DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 369 BELGIUM FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 370 BELGIUM MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 371 BELGIUM DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 372 BELGIUM HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 373 BELGIUM HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 374 BELGIUM DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 375 BELGIUM RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 376 NETHERLANDS DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 377 NETHERLANDS DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 378 NETHERLANDS MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 379 NETHERLANDS DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 380 NETHERLANDS ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 381 NETHERLANDS PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 382 NETHERLANDS PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 383 NETHERLANDS PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 384 NETHERLANDS H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 385 NETHERLANDS H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 386 NETHERLANDS H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 387 NETHERLANDS GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 388 NETHERLANDS GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 389 NETHERLANDS GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 390 NETHERLANDS ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 391 NETHERLANDS ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 392 NETHERLANDS ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 393 NETHERLANDS NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 394 NETHERLANDS PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 395 NETHERLANDS PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 396 NETHERLANDS PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 397 NETHERLANDS DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 398 NETHERLANDS DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 399 NETHERLANDS DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 400 NETHERLANDS ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 401 NETHERLANDS DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 402 NETHERLANDS FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 403 NETHERLANDS MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 404 NETHERLANDS DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 405 NETHERLANDS HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 406 NETHERLANDS HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 407 NETHERLANDS DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 408 NETHERLANDS RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 409 DENMARK DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 410 DENMARK DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 411 DENMARK MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 412 DENMARK DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 413 DENMARK ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 414 DENMARK PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 415 DENMARK PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 416 DENMARK PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 417 DENMARK H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 418 DENMARK H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 419 DENMARK H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 420 DENMARK GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 421 DENMARK GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 422 DENMARK GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 423 DENMARK ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 424 DENMARK ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 425 DENMARK ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 426 DENMARK NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 427 DENMARK PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 428 DENMARK PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 429 DENMARK PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 430 DENMARK DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 431 DENMARK DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 432 DENMARK DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 433 DENMARK ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 434 DENMARK DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 435 DENMARK FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 436 DENMARK MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 437 DENMARK DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 438 DENMARK HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 439 DENMARK HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 440 DENMARK DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 441 DENMARK RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 442 SWEDEN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 443 SWEDEN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 444 SWEDEN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 445 SWEDEN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 446 SWEDEN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 447 SWEDEN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 448 SWEDEN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 449 SWEDEN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 450 SWEDEN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 451 SWEDEN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 452 SWEDEN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 453 SWEDEN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 454 SWEDEN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 455 SWEDEN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 456 SWEDEN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 457 SWEDEN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 458 SWEDEN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 459 SWEDEN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 460 SWEDEN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 461 SWEDEN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 462 SWEDEN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 463 SWEDEN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 464 SWEDEN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 465 SWEDEN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 466 SWEDEN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 467 SWEDEN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 468 SWEDEN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 469 SWEDEN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 470 SWEDEN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 471 SWEDEN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 472 SWEDEN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 473 SWEDEN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 474 POLAND DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 475 POLAND DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 476 POLAND MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 477 POLAND DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 478 POLAND ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 479 POLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 480 POLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 481 POLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 482 POLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 483 POLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 484 POLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 485 POLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 486 POLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 487 POLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 488 POLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 489 POLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 490 POLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 491 POLAND NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 492 POLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 493 POLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 494 POLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 495 POLAND DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 496 POLAND DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 497 POLAND DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 498 POLAND ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 499 POLAND DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 500 POLAND FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 501 POLAND MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 502 POLAND DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 503 POLAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 504 POLAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 505 POLAND DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 506 POLAND RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 507 NORWAY DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 508 NORWAY DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 509 NORWAY MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 510 NORWAY DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 511 NORWAY ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 512 NORWAY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 513 NORWAY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 514 NORWAY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 515 NORWAY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 516 NORWAY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 517 NORWAY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 518 NORWAY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 519 NORWAY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 520 NORWAY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 521 NORWAY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 522 NORWAY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 523 NORWAY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 524 NORWAY NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 525 NORWAY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 526 NORWAY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 527 NORWAY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 528 NORWAY DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 529 NORWAY DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 530 NORWAY DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 531 NORWAY ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 532 NORWAY DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 533 NORWAY FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 534 NORWAY MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 535 NORWAY DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 536 NORWAY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 537 NORWAY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 538 NORWAY DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 539 NORWAY RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 540 FINLAND DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 541 FINLAND DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 542 FINLAND MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 543 FINLAND DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 544 FINLAND ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 545 FINLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 546 FINLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 547 FINLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 548 FINLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 549 FINLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 550 FINLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 551 FINLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 552 FINLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 553 FINLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 554 FINLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 555 FINLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 556 FINLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 557 FINLAND NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 558 FINLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 559 FINLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 560 FINLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 561 FINLAND DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 562 FINLAND DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 563 FINLAND DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 564 FINLAND ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 565 FINLAND DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 566 FINLAND FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 567 FINLAND MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 568 FINLAND DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 569 FINLAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 570 FINLAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 571 FINLAND DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 572 FINLAND RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 573 REST OF EUROPE DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
Liste des figures
FIGURE 1 EUROPE DYSPEPSIA DRUG MARKET: SEGMENTATION
FIGURE 2 EUROPE DYSPEPSIA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE DYSPEPSIA DRUG MARKET: DROC ANALYSIS
FIGURE 4 EUROPE DYSPEPSIA DRUG MARKET: EUROPE VS. REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE DYSPEPSIA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE DYSPEPSIA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE DYSPEPSIA DRUG MARKET: MULTIVARIATE MODELLING
FIGURE 8 EUROPE DYSPEPSIA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE DYSPEPSIA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE DYSPEPSIA DRUG MARKET: MARKET END-USER COVERAGE GRID
FIGURE 11 EUROPE DYSPEPSIA DRUG MARKET: SEGMENTATION
FIGURE 12 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS IS EXPECTED TO DRIVE THE EUROPE DYSPEPSIA DRUG MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030
FIGURE 13 NON-ULCER DYSPEPSIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DYSPEPSIA DRUG MARKET IN 2023 & 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE DYSPEPSIA DRUG MARKET
FIGURE 15 EUROPE DYSPEPSIA DRUG MARKET: BY TYPE, 2022
FIGURE 16 EUROPE DYSPEPSIA DRUG MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 17 EUROPE DYSPEPSIA DRUG MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 18 EUROPE DYSPEPSIA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 EUROPE DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , 2022
FIGURE 20 EUROPE DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 21 EUROPE DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , CAGR (2023-2030)
FIGURE 22 EUROPE DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , LIFELINE CURVE
FIGURE 23 EUROPE DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2022
FIGURE 24 EUROPE DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)
FIGURE 25 EUROPE DYSPEPSIA DRUG MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 26 EUROPE DYSPEPSIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 27 EUROPE DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2022
FIGURE 28 EUROPE DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2023-2030 (USD THOUSAND)
FIGURE 29 EUROPE DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, CAGR (2023-2030)
FIGURE 30 EUROPE DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, LIFELINE CURVE
FIGURE 31 EUROPE DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 32 EUROPE DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 33 EUROPE DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 34 EUROPE DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 EUROPE DYSPEPSIA DRUG MARKET: BY GENDER, 2022
FIGURE 36 EUROPE DYSPEPSIA DRUG MARKET: BY GENDER, 2023-2030 (USD THOUSAND)
FIGURE 37 EUROPE DYSPEPSIA DRUG MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 38 EUROPE DYSPEPSIA DRUG MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 EUROPE DYSPEPSIA DRUG MARKET: BY END USER, 2022
FIGURE 40 EUROPE DYSPEPSIA DRUG MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 41 EUROPE DYSPEPSIA DRUG MARKET: BY END USER, CAGR (2023-2030)
FIGURE 42 EUROPE DYSPEPSIA DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 EUROPE DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 44 EUROPE DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 45 EUROPE DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 46 EUROPE DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 EUROPE DYSPEPSIA DRUG MARKET: SNAPSHOT (2022)
FIGURE 48 EUROPE DYSPEPSIA DRUG MARKET: BY COUNTRY (2022)
FIGURE 49 EUROPE DYSPEPSIA DRUG MARKET: BY COUNTRY (2023 & 2030)
FIGURE 50 EUROPE DYSPEPSIA DRUG MARKET: BY COUNTRY (2022 & 2030)
FIGURE 51 EUROPE DYSPEPSIA DRUG MARKET: BY TYPE (2023-2030)
FIGURE 52 EUROPE DYSPEPSIA DRUG MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
